Glenmark Pharmaceuticals has informed about submission of media release titled ‘Glenmark Receives Orphan Drug Designation for GBR 1342, a Bispecific Antibody Candidate Under Evaluation for the Treatment of Multiple Myeloma’, which is self explanatory.
The above information is a part of company’s filings submitted to BSE.